Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. Read more
Many people have misconceptions about clinical trials. These images help to correct these misconceptions..
by Deb Maskens, Kidney Cancer Canada
The American Society of Clinical Oncology (ASCO) held its annual Genitourinary (GU) Cancers Symposium in San Francisco from January 7-9.
The theme of this year’s Symposium was “Patient-Centric Care: Translating Research to Results”. The program included localized and advanced disease, immunotherapy and health care outcomes. The program was bursting with kidney cancer content including 19 presentations, 129 posters and 2 evening ancillary meetings. It was
Has Immune Checkpoint blockade re-established immunotherapy as a Key Pillar of Kidney cancer care? A panel led by Dr. Michael Atkins discusses the current state of immuno-oncology for kidney cancer.
IKCC launches an educational website for immuno-oncology for kidney cancer. Powerful Patient interviews Deb Maskens about this effort and its goals.
The publication in 2015 of results of two pivotal clinical trials were sufficiently compelling that the Guidelines Committee of the European Assocation of Urology has modified its Guidelines. The modified advisory was published in European Urology.